Julia M.W. Gee
YOU?
Author Swipe
View article: A statistical approach to automated analysis of the low‐contrast object detectability test for the large ACR MRI phantom
A statistical approach to automated analysis of the low‐contrast object detectability test for the large ACR MRI phantom Open
Background Regular quality control checks are essential to ensure the quality of MRI systems. The American College of Radiology (ACR) has developed a standardized large phantom test protocol for this purpose. However, the ACR protocol reco…
View article: Oxidative Stress-Responsive 1 Kinase Catalytic Activity Promotes Triple Negative Breast Cancer Oncogenic Potential
Oxidative Stress-Responsive 1 Kinase Catalytic Activity Promotes Triple Negative Breast Cancer Oncogenic Potential Open
The protein kinase OSR1 has been highlighted as a biomarker for a poor prognosis in breast cancer (BC) patients. To further decipher the mechanism underpinning this, we studied the expression, phosphorylation status, and catalytic activity…
View article: Smart Compression Sock for Early Detection of Diabetic Foot Ulcers
Smart Compression Sock for Early Detection of Diabetic Foot Ulcers Open
The prevention of diabetic foot ulcers remains a critical challenge. This study evaluates a smart compression sock designed to address this issue by integrating temperature, plantar pressure, and blood oxygen sensors and monitoring data re…
View article: Assessing Susceptibility to Carbon Dioxide Gas in Three Rat Strains Using the Loss of Righting Reflex
Assessing Susceptibility to Carbon Dioxide Gas in Three Rat Strains Using the Loss of Righting Reflex Open
Overdose of carbon dioxide gas (CO 2 ) is a common euthanasia method for rodents; however, CO 2 exposure activates nociceptors in rats at concentrations equal to or greater than 37% and is reported to be painful in humans at concentrations…
View article: The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer
The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer Open
Three-dimensional (3D) epigenome remodeling is an important mechanism of gene deregulation in cancer. However, its potential as a target to counteract therapy resistance remains largely unaddressed. Here, we show that epigenetic therapy wi…
View article: Use of Loss of Righting Reflex to Assess Susceptibility to Carbon Dioxide Gas in Three Mouse Strains
Use of Loss of Righting Reflex to Assess Susceptibility to Carbon Dioxide Gas in Three Mouse Strains Open
Exposure to CO 2 gas is a common rodent euthanasia method. CO 2 activates nociceptors in rats and is painful to humans at concentrations equal to or greater than 32.5% The concentration of CO 2 at which rodents become unconsciousness is in…
View article: Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial
Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial Open
View article: Expression of proteins involved in mitochondrial fusion, fission and energy production is altered by age, sex and Alzheimer’s disease
Expression of proteins involved in mitochondrial fusion, fission and energy production is altered by age, sex and Alzheimer’s disease Open
Background Age is the biggest risk factor for Alzheimer’s disease (AD) but being female also increases risk with ∼63% of AD patients being female. This sex difference could partly be explained by menopause‐related oestrogen deficiencies du…
View article: Supplementary Figure 2 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Supplementary Figure 2 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
PDF - 664KB, BCL-2 Gene expression vs methylation status.
View article: Supplementary Figure 4 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Supplementary Figure 4 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
PDF - 4365KB, BCL-2 Methylation vs disease free survival.
View article: Supplementary Figure 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Figure 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 78KB, Supplementary Figure 2: Deregulation of cyclin E in tamoxifen-resistant cells. MCF-7C and TAMR cells were treated with vehicle, OH-Tam (100 nM) or fulvestrant (10 nM). A: S phase percentage derived from flow cytometry of pr…
View article: Supplementary Figure 2 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Supplementary Figure 2 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
PDF - 664KB, BCL-2 Gene expression vs methylation status.
View article: Data from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Data from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
Overexpression of the antiapoptotic factor BCL-2 is a frequent feature of malignant disease and is commonly associated with poor prognosis and resistance to conventional chemotherapy. In breast cancer, however, high BCL-2 expression is ass…
View article: Supplementary Figure 5 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Supplementary Figure 5 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
PDF - 221KB, A. Plk1 Expression vs relapse-free survival in endocrine treated ER-positive breast cancer patients (n=287). B. Correlative analysis of ER, BCL-2 and PLK1 gene expression in TCGA breast cohort (n=774).
View article: Supplementary Figure 3 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Figure 3 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 41KB, Supplementary Figure 3: Effect of overexpression of cyclins E1 and E2 on antiestrogen-induced growth arrest. T-47D cells overexpressing cyclin E1, cyclin E2 or vector control were treated with fulvestrant or vehicle. Densit…
View article: Supplementary Methods, Figure Legends and Tables 1 - 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Methods, Figure Legends and Tables 1 - 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 56KB.
View article: Supplementary Figure 3 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Supplementary Figure 3 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
PDF - 459KB, BCL-2 Methylation status in cancer vs normal tissue.
View article: Supplementary Materials and Methods from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Supplementary Materials and Methods from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
PDF - 51KB, PLK1 gene expression/survival analysis.
View article: Supplementary Figure 1 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Figure 1 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 929KB, Supplementary Figure 1: Cyclin E2 association with breast cancer subtype, grade, and outcome. A: Relationship between a second cyclin E2 probeset and breast cancer subtype, or histological grade. Box: upper and lower quart…
View article: Supplementary Figure 1 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Figure 1 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 929KB, Supplementary Figure 1: Cyclin E2 association with breast cancer subtype, grade, and outcome. A: Relationship between a second cyclin E2 probeset and breast cancer subtype, or histological grade. Box: upper and lower quart…
View article: Supplementary Figure 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Figure 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 78KB, Supplementary Figure 2: Deregulation of cyclin E in tamoxifen-resistant cells. MCF-7C and TAMR cells were treated with vehicle, OH-Tam (100 nM) or fulvestrant (10 nM). A: S phase percentage derived from flow cytometry of pr…
View article: Supplementary Figure 4 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Supplementary Figure 4 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
PDF - 4365KB, BCL-2 Methylation vs disease free survival.
View article: Supplementary Figure 3 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Supplementary Figure 3 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
PDF - 459KB, BCL-2 Methylation status in cancer vs normal tissue.
View article: Supplementary Figure 1 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Supplementary Figure 1 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
PDF - 289KB, BCL-2 450K Methylation array probes (n=42).
View article: Supplementary Methods, Figure Legends and Tables 1 - 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Methods, Figure Legends and Tables 1 - 2 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 56KB.
View article: Data from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Data from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
Cyclin E2, but not cyclin E1, is included in several gene signatures that predict disease progression in either tamoxifen-resistant or metastatic breast cancer. We therefore examined the role of cyclin E2 in antiestrogen resistance in v…
View article: Data from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Data from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
Overexpression of the antiapoptotic factor BCL-2 is a frequent feature of malignant disease and is commonly associated with poor prognosis and resistance to conventional chemotherapy. In breast cancer, however, high BCL-2 expression is ass…
View article: Supplementary Figure 6 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Supplementary Figure 6 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
PDF - 80KB, The effect of BI2536 in endocrine-sensitive and endocrine-resistant breast cancer cells.
View article: Supplementary Figure 6 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Supplementary Figure 6 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer Open
PDF - 80KB, The effect of BI2536 in endocrine-sensitive and endocrine-resistant breast cancer cells.
View article: Supplementary Figure 3 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
Supplementary Figure 3 from Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells Open
PDF file, 41KB, Supplementary Figure 3: Effect of overexpression of cyclins E1 and E2 on antiestrogen-induced growth arrest. T-47D cells overexpressing cyclin E1, cyclin E2 or vector control were treated with fulvestrant or vehicle. Densit…